{"id":4706,"date":"2025-03-31T18:12:17","date_gmt":"2025-03-31T18:12:17","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/synercid-txt\/"},"modified":"2025-03-31T18:12:17","modified_gmt":"2025-03-31T18:12:17","slug":"synercid-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/synercid-txt\/","title":{"rendered":"synercid.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nAntibacterial agent

DOSE IN NORMAL RENAL FUNCTION <\/H3>7.5 mg\/kg every 8 hours

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :1118.3 (quinupristin); 787 (dalfopristin) \u2013 as mesilate<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :55\u201378 (quinupristin); 11\u201326 (dalfopristin)<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 15 (quinupristin); 19 (dalfopristin)<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.45 (quinupristin); 0.24 (dalfopristin)<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :0.9 (quinupristin); 0.7 (dalfopristin)

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : 5\u20137.5 mg\/kg 8\u201312 hourly
  • 10 to 20 &nbsp &nbsp : 5\u20137.5 mg\/kg 8\u201312 hourly
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 5 mg\/kg 8\u201312 hourly

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed.
  • 10 to 20 &nbsp &nbsp : mg\/kg\/day in 2 divided doses1<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anti-arrhythmics: increased risk of ventricular arrhythmias with disopyramide and lidocaine \u2013 avoid concomitant useAnxiolytics and hypnotics: increased concentration of midazolam (risk of profound sedation); metabolism of zopiclone inhibited\n
  • Calcium-channel blockers: increased concentration of nifedipine\n
  • Ciclosporin: increased levels of ciclosporin\n
  • Ergot alkaloids: avoid concomitant use with ergotamine and methysergide\n
  • Tacrolimus: tacrolimus levels increased by 15%

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>With 5 mL glucose 5% or water for injection

    Route <\/H4>

    IV infusion <\/H4> through a central line

    Rate of Administration <\/H4>Over 60 minutes

    Comments<\/H4>Central access is recommended: Dilute reconstituted solution further in \u2014100 mL glucose 5% for central access Or 250 mL for peripheral access (for \u2014emergency administration of 1st dose only). Stable for 5 hours at room temperature and 24 hours if refrigeratedIncompatible with saline solutions

    OTHER INFORMATION <\/H4>After the infusion, flush the line with glucose 5% to minimise venous irritationHas been administered intraperitoneally at a dose of 25 mg\/L in alternate bags, in combination with intravenous treatmentSynercid is an inhibitor of CYP 3A4: caution is recommended when co-administering any drug also metabolised by this route
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Antibacterial agent DOSE IN NORMAL RENAL FUNCTION 7.5<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4706","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4706","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4706"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4706\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4706"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}